Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
36
CXXI.CX Quote, Financials, Valuation and Earnings
Last price:
$0.44
Seasonality move
:
20.84%
Day range:
$0.44 - $0.51
52-week range:
$0.15 - $0.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.13x
P/B ratio:
1.36x
Volume:
134.7K
Avg. volume:
85.9K
1-year change:
54.39%
Market cap:
$51.9M
Revenue:
$41.9M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CXXI.CX
C21 Investments, Inc.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CXXI.CX
C21 Investments, Inc.
|
$0.44 | -- | $51.9M | -- | $0.00 | 0% | 1.13x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $8.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CXXI.CX
C21 Investments, Inc.
|
29.29% | 2.703 | 26.73% | 0.52x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CXXI.CX
C21 Investments, Inc.
|
$5.3M | $1.7M | -6.88% | -9.95% | 14.5% | $579.2K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
C21 Investments, Inc. vs. Competitors
-
Which has Higher Returns CXXI.CX or COOL.CX?
Core One Labs, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.95% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CXXI.CXC21 Investments, Inc.45.15% -$0.01 $53.8M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About CXXI.CX or COOL.CX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that C21 Investments, Inc. has higher upside potential than Core One Labs, Inc., analysts believe C21 Investments, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXI.CXC21 Investments, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is CXXI.CX or COOL.CX More Risky?
C21 Investments, Inc. has a beta of 2.056, which suggesting that the stock is 105.64% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock CXXI.CX or COOL.CX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXI.CX or COOL.CX?
C21 Investments, Inc. quarterly revenues are $11.7M, which are larger than Core One Labs, Inc. quarterly revenues of --. C21 Investments, Inc.'s net income of -$663.4K is higher than Core One Labs, Inc.'s net income of --. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.13x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXI.CXC21 Investments, Inc.1.13x -- $11.7M -$663.4K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns CXXI.CX or CURE.X.CX?
Biocure Technology has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.95% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CXXI.CXC21 Investments, Inc.45.15% -$0.01 $53.8M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About CXXI.CX or CURE.X.CX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that C21 Investments, Inc. has higher upside potential than Biocure Technology, analysts believe C21 Investments, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings CXXI.CXC21 Investments, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is CXXI.CX or CURE.X.CX More Risky?
C21 Investments, Inc. has a beta of 2.056, which suggesting that the stock is 105.64% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CXXI.CX or CURE.X.CX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXI.CX or CURE.X.CX?
C21 Investments, Inc. quarterly revenues are $11.7M, which are larger than Biocure Technology quarterly revenues of --. C21 Investments, Inc.'s net income of -$663.4K is higher than Biocure Technology's net income of --. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.13x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXI.CXC21 Investments, Inc.1.13x -- $11.7M -$663.4K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns CXXI.CX or HEAL.CX?
has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.95% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CXXI.CXC21 Investments, Inc.45.15% -$0.01 $53.8M HEAL.CX-- -- -- -
What do Analysts Say About CXXI.CX or HEAL.CX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that C21 Investments, Inc. has higher upside potential than , analysts believe C21 Investments, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings CXXI.CXC21 Investments, Inc.0 0 0 HEAL.CX0 0 0 -
Is CXXI.CX or HEAL.CX More Risky?
C21 Investments, Inc. has a beta of 2.056, which suggesting that the stock is 105.64% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CXXI.CX or HEAL.CX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXI.CX or HEAL.CX?
C21 Investments, Inc. quarterly revenues are $11.7M, which are larger than quarterly revenues of --. C21 Investments, Inc.'s net income of -$663.4K is higher than 's net income of --. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.13x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXI.CXC21 Investments, Inc.1.13x -- $11.7M -$663.4K HEAL.CX-- -- -- --
-
Which has Higher Returns CXXI.CX or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.95% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CXXI.CXC21 Investments, Inc.45.15% -$0.01 $53.8M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About CXXI.CX or LOBE.CX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 15780.37%. Given that Lobe Sciences Ltd. has higher upside potential than C21 Investments, Inc., analysts believe Lobe Sciences Ltd. is more attractive than C21 Investments, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXI.CXC21 Investments, Inc.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is CXXI.CX or LOBE.CX More Risky?
C21 Investments, Inc. has a beta of 2.056, which suggesting that the stock is 105.64% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock CXXI.CX or LOBE.CX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXI.CX or LOBE.CX?
C21 Investments, Inc. quarterly revenues are $11.7M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. C21 Investments, Inc.'s net income of -$663.4K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.13x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXI.CXC21 Investments, Inc.1.13x -- $11.7M -$663.4K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns CXXI.CX or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -5.69% compared to C21 Investments, Inc.'s net margin of --. C21 Investments, Inc.'s return on equity of -9.95% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CXXI.CXC21 Investments, Inc.45.15% -$0.01 $53.8M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About CXXI.CX or NSHS.CX?
C21 Investments, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that C21 Investments, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe C21 Investments, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CXXI.CXC21 Investments, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is CXXI.CX or NSHS.CX More Risky?
C21 Investments, Inc. has a beta of 2.056, which suggesting that the stock is 105.64% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock CXXI.CX or NSHS.CX?
C21 Investments, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C21 Investments, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CXXI.CX or NSHS.CX?
C21 Investments, Inc. quarterly revenues are $11.7M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. C21 Investments, Inc.'s net income of -$663.4K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, C21 Investments, Inc.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C21 Investments, Inc. is 1.13x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CXXI.CXC21 Investments, Inc.1.13x -- $11.7M -$663.4K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
